{"title":"The Role of Clinical Pharmacist in Reducing Drug Related Problems in Decompensated Liver cirrhosis patients","authors":"Ameer Alobeidi, None Mohammed Y. Jamal","doi":"10.31351/vol32iss2pp1-8","DOIUrl":null,"url":null,"abstract":"Patients with decompensated cirrhosis have typically prescribed a combination of therapeutic and prophylactic medications. Polypharmacy increases the probability of medication errors and drug related problems. Clinical pharmacists are highly effective at identifying, resolving, and preventing clinically important drug-related problems in their patients' care. The objectives of the study were the identification and classification of drug-related problems, as well as the discussion of these problems with health care providers (physicians, pharmacists, and nurses) and patients. Reduce their incidence as effectively as possible and educate all research participants on the significance of following their prescribed drug regimen. Prospective, interventional, clinical study for 80 hospitalized decompensated liver cirrhosis patients was designed in two phases, an observational phase to identify drug related problems and classify them according to the Pharmaceutical Care Network Europe classification version 9.1, and an interventional phase to increase the awareness of patients and the health care providers about those problems and to propose a proper solution for each one. The majority of drug-related problems were attributable to the Effect of drug treatment not optimal in 41.5%, Adverse drug events (possibly) occurring in 41.5 %, and Untreated symptoms or indications in 17%. Causes were Drug dose too high in 30.2%, Patient unintentionally using the drug in the wrong way in 22.6%, and Prescribed drug not available in 13.2%. Omeprazole and lactulose were the most common medications causing problems. Acceptance and full implementation were high and observed in 71.7% of pharmacist interventions while 15.1% of the intervention have no agreement. Significant numbers of Iraqi patients with decompensated liver cirrhosis have drug-related problems, and the use of proton pump inhibitors in too high dose was accountable for a large number of problems. Physicians and clinical pharmacists collaborated exceptionally well","PeriodicalId":14600,"journal":{"name":"Iraqi Journal of Pharmaceutical Sciences","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iraqi Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31351/vol32iss2pp1-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Patients with decompensated cirrhosis have typically prescribed a combination of therapeutic and prophylactic medications. Polypharmacy increases the probability of medication errors and drug related problems. Clinical pharmacists are highly effective at identifying, resolving, and preventing clinically important drug-related problems in their patients' care. The objectives of the study were the identification and classification of drug-related problems, as well as the discussion of these problems with health care providers (physicians, pharmacists, and nurses) and patients. Reduce their incidence as effectively as possible and educate all research participants on the significance of following their prescribed drug regimen. Prospective, interventional, clinical study for 80 hospitalized decompensated liver cirrhosis patients was designed in two phases, an observational phase to identify drug related problems and classify them according to the Pharmaceutical Care Network Europe classification version 9.1, and an interventional phase to increase the awareness of patients and the health care providers about those problems and to propose a proper solution for each one. The majority of drug-related problems were attributable to the Effect of drug treatment not optimal in 41.5%, Adverse drug events (possibly) occurring in 41.5 %, and Untreated symptoms or indications in 17%. Causes were Drug dose too high in 30.2%, Patient unintentionally using the drug in the wrong way in 22.6%, and Prescribed drug not available in 13.2%. Omeprazole and lactulose were the most common medications causing problems. Acceptance and full implementation were high and observed in 71.7% of pharmacist interventions while 15.1% of the intervention have no agreement. Significant numbers of Iraqi patients with decompensated liver cirrhosis have drug-related problems, and the use of proton pump inhibitors in too high dose was accountable for a large number of problems. Physicians and clinical pharmacists collaborated exceptionally well
失代偿性肝硬化患者通常使用治疗性和预防性联合用药。多种用药增加了用药错误和药物相关问题的可能性。临床药师在识别、解决和预防患者护理中临床上重要的药物相关问题方面非常有效。该研究的目的是识别和分类与药物有关的问题,以及与卫生保健提供者(医生、药剂师和护士)和患者讨论这些问题。尽可能有效地减少其发生率,并教育所有研究参与者遵守其处方药物方案的重要性。本研究对80例住院失代偿期肝硬化患者进行前瞻性、干预性临床研究,分为两个阶段:观察阶段识别药物相关问题,并根据欧洲药学保健网络(Pharmaceutical Care Network Europe) 9.1版分类标准对其进行分类;介入阶段提高患者和医护人员对药物相关问题的认识,并针对每个问题提出适当的解决方案。41.5%的药物相关问题可归因于药物治疗效果不佳,41.5%的药物不良事件(可能)发生,17%的症状或指征未得到治疗。病因为用药剂量过高(30.2%)、患者误用(22.6%)和无法获得处方药物(13.2%)。奥美拉唑和乳果糖是最常见的导致问题的药物。71.7%的药师干预措施的接受度和完全执行度较高,15.1%的药师干预措施不一致。大量伊拉克失代偿性肝硬化患者有药物相关问题,过高剂量使用质子泵抑制剂是造成大量问题的原因。医生和临床药剂师合作得非常好